Research and Markets (http://www.researchandmarkets.com/research/fe4133/urological_disorde)
has announced the addition of the Urological
Disorders Therapeutics to 2016 - Increasing Awareness and Aging
Population will Drive the Benign Prostatic Hyperplasia and Urinary
Incontinence Markets report to their offering.
“Urological
Disorders Therapeutics to 2016 - Increasing Awareness and Aging
Population will Drive the Benign Prostatic Hyperplasia and Urinary
Incontinence Markets”
Urological
Disorders Therapeutics to 2016 - Increasing Awareness and Aging
Population will Drive the Benign Prostatic Hyperplasia and Urinary
Incontinence Markets. It provides in-depth analysis of the unmet
needs, drivers and barriers that affect the global urological disorders
therapeutics market. The report analyzes the markets for urological
disorders in the US, the top five countries in Europe (the UK, Germany,
France, Italy and Spain) and Japan. Treatment usage patterns, sales
value and annual cost of therapy are forecast until 2016 for key
geographies in the leading therapeutic segments. Further, the report
provides competitive benchmarking for the leading companies and analyzes
the mergers and acquisitions (M&A) and licensing agreements that shape
the global markets.
The report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by a
team of industry experts.
Global Urological Disorders Market
The authors indicate that the global urological disorders market has
been one of the fastest growing markets in the pharmaceutical industry.
However, the market growth is expected to slow down in the future due to
various restraints such as the expiry of key drugs patents across all
disease segments, entry of generic, and decreased annual cost of therapy
in major markets such as the US, Japan and the top five countries in
Europe. Nevertheless, the global urological disorders market is still
forecast to grow at a moderate rate in the future.
The Global Urological Disorders Market is Forecast to Show Moderate
Growth
In 2009, the global urological disorders market was estimated to be
worth $7.9 billion, representing a cumulative annual growth rate (CAGR)
of 9.6% between 2001 and 2009. The market is forecast to reach $9.8
billion by 2016, indicating a CAGR of 3.1% between 2009 and 2016. The
primary reason for the reduced growth rate is the patent expiries of
major blockbusters, which subsequently is expected to decline the annual
cost of therapy after 2009.
The global urological disorders market is expected to witness a series
of patent expiries between 2009 and 2016, which includes most of the top
selling blockbuster drugs in the Urinary Incontinence (UI), Benign
Prostatic Hyperplasia (BPH) and Urinary Tract Infections (UTI) market.
The major drugs that are set to lose patent protection include Flomax
(2009), Levaquin (2010), Uroxatral - in US (2011), Detrol (2012),
Avodart (2015), Enablex (2015) and Ditropan XL (2015). All these drugs
together account for more than $6.3 billion of revenues in the global
urological disorders market.
The current urological disorders pipeline does offer some promising
novel products. However, the revenues generated from these products are
not expected to completely make up for the revenues lost due to patent
expiries. Thus, the overall market growth of the global urological
disorders market is expected to decline during the forecast period.
Scope
Annualized market data for the urological disorders market from 2001
to 2009, forecast forward to 2016.
Analysis of the leading therapeutic segments, including Urinary
Incontinence (UI), Benign Prostatic Hyperplasia (BPH) and Urinary
Tract Infections (UTI).
Analysis of the urological disorders market in the leading geographies
of the world, which include the US (United States), the UK (United
Kingdom), Germany, France, Italy, Spain and Japan.
Market characterization of the urological disorders market, including
market size, annual cost of therapy and treatment usage patterns.
Key drivers and barriers that have a significant impact on the market.
Coverage of pipeline molecules in various phases of drug development.
Competitive benchmarking of leading companies. The key companies
studied in this report are Allergen Inc, Astellas Pharma, Pfizer Inc,
Novexel SA, Eli Lilly and Company, GSK, Sanofi-- Aventis, Johnson and
Johnson and Protox Therapeutics, Inc.
Key M&A activities, licensing agreements that have taken place between
2004 and mid-2010 in the global urological disorders market.
Reasons to buy
Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying
the leading therapeutic segments and geographic markets poised for
strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can
produce first-in-class molecules with more efficiency and better
safety.
Develop key strategic initiatives by understanding the key focus areas
of leading companies.
Exploit in-licensing and out-licensing opportunities by identifying
products that could fill portfolio gaps.
Key Topics Covered:
Global Urological Disorders Market: Introduction
Global Urological Disorders Market: Market Overview
Global Urological Disorders Market: Therapeutic Landscape
Global Urological Disorders Market: Geographical Landscape
Global Urological Disorders Market: Pipeline Analysis
Global Urological Disorders Market: Competitive Landscape
Global Urological Disorders Market: Strategic Consolidations
Global Urological Disorders Market: Appendix
Companies Mentioned:
Astellas Pharma
Johnson and Johnson (J&J)
Pfizer
GlaxoSmithKilne (GSK)
Sanofi-Aventis
For more information visit http://www.researchandmarkets.com/research/fe4133/urological_disorde
Source: Business Wire